Literature DB >> 27188195

Resistant Hypertension: An Incurable Disease or Just a Challenge For Our Medical Skill?

Marina Di Pilla1, Rosa Maria Bruno1, Stefano Taddei2.   

Abstract

Resistant hypertension is classically defined as a clinical condition in which target blood pressure values of 140/90 mmHg are not achieved despite an optimal pharmacological therapy of at least three antihypertensive drugs, including a diuretic. The aim of this review is to give an outline of the nosography of this disorder, highlighting the differences between true and apparent resistant hypertension. Since the proportions of patients who can be defined as resistant to antihypertensive treatment is elevated, this distinction is mandatory in order to identify only those who need special clinical attention and, possibly, newer non-traditional techniques. While at first glance resistant hypertension may appear as an insuperable problem, an accurate clinical work-up of these patients, aimed at excluding reversible causes and optimizing pharmacological treatment, represents an effective solution in most cases.

Entities:  

Keywords:  Ambulatory blood pressure; Definition; Pseudoresistance; Resistant hypertension

Mesh:

Substances:

Year:  2016        PMID: 27188195     DOI: 10.1007/s40292-016-0159-y

Source DB:  PubMed          Journal:  High Blood Press Cardiovasc Prev        ISSN: 1120-9879


  44 in total

1.  Position paper on the management of patients with obstructive sleep apnea and hypertension: joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of European COST (COoperation in Scientific and Technological research) ACTION B26 on obstructive sleep apnea.

Authors:  Gianfranco Parati; Carolina Lombardi; Jan Hedner; Maria R Bonsignore; Ludger Grote; Ruzena Tkacova; Patrick Levy; Renata Riha; Claudio Bassetti; Krzysztof Narkiewicz; Giuseppe Mancia; Walter T McNicholas
Journal:  J Hypertens       Date:  2012-04       Impact factor: 4.844

2.  Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension.

Authors:  Mari K Nishizaka; Monique Pratt-Ubunama; Mohammad A Zaman; Stacey Cofield; David A Calhoun
Journal:  Am J Hypertens       Date:  2005-06       Impact factor: 2.689

3.  Hypertension in adults across the age spectrum: current outcomes and control in the community.

Authors:  Donald M Lloyd-Jones; Jane C Evans; Daniel Levy
Journal:  JAMA       Date:  2005-07-27       Impact factor: 56.272

4.  Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial.

Authors:  Melvin D Lobo; Paul A Sobotka; Alice Stanton; John R Cockcroft; Neil Sulke; Eamon Dolan; Markus van der Giet; Joachim Hoyer; Stephen S Furniss; John P Foran; Adam Witkowski; Andrzej Januszewicz; Danny Schoors; Konstantinos Tsioufis; Benno J Rensing; Benjamin Scott; G André Ng; Christian Ott; Roland E Schmieder
Journal:  Lancet       Date:  2015-01-23       Impact factor: 79.321

5.  High prevalence of unrecognized sleep apnoea in drug-resistant hypertension.

Authors:  A G Logan; S M Perlikowski; A Mente; A Tisler; R Tkacova; M Niroumand; R S Leung; T D Bradley
Journal:  J Hypertens       Date:  2001-12       Impact factor: 4.844

6.  Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension.

Authors:  Rodrigo P Pedrosa; Luciano F Drager; Carolina C Gonzaga; Marcio G Sousa; Lílian K G de Paula; Aline C S Amaro; Celso Amodeo; Luiz A Bortolotto; Eduardo M Krieger; T Douglas Bradley; Geraldo Lorenzi-Filho
Journal:  Hypertension       Date:  2011-10-03       Impact factor: 10.190

7.  Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research.

Authors:  Thomas G Pickering; John E Hall; Lawrence J Appel; Bonita E Falkner; John Graves; Martha N Hill; Daniel W Jones; Theodore Kurtz; Sheldon G Sheps; Edward J Roccella
Journal:  Circulation       Date:  2005-02-08       Impact factor: 29.690

8.  Non-narcotic analgesic dose and risk of incident hypertension in US women.

Authors:  John P Forman; Meir J Stampfer; Gary C Curhan
Journal:  Hypertension       Date:  2005-08-15       Impact factor: 10.190

9.  Clinical management of resistant hypertension: practical recommendations from the Italian Society of Hypertension (SIIA).

Authors:  Franco Veglio; Guido Grassi; Giuseppe Mancia; Massimo Volpe
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-08-15

10.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Authors:  Bryan Williams; Thomas M MacDonald; Steve Morant; David J Webb; Peter Sever; Gordon McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Jackie Salsbury; Isla Mackenzie; Sandosh Padmanabhan; Morris J Brown
Journal:  Lancet       Date:  2015-09-20       Impact factor: 79.321

View more
  1 in total

1.  Increased Incidence of Resistant Hypertension in Patients With Systemic Lupus Erythematosus: A Retrospective Cohort Study.

Authors:  Jocelyn S Gandelman; Omair A Khan; Megan M Shuey; Jacquelyn E Neal; Elizabeth McNeer; Alyson Dickson; April Barnado; Li Wang; Prathima Anandi; William D Dupont; C Michael Stein; Cecilia P Chung
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-04       Impact factor: 4.794

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.